|
US20050060764A1
(en)
*
|
2003-09-17 |
2005-03-17 |
Susan Gregory |
Mouse model for bone metabolism
|
|
IL117175A
(en)
|
1995-02-20 |
2005-11-20 |
Sankyo Co |
Osteoclastogenesis inhibitory factor protein
|
|
US6919434B1
(en)
|
1995-02-20 |
2005-07-19 |
Sankyo Co., Ltd. |
Monoclonal antibodies that bind OCIF
|
|
US20050147611A1
(en)
*
|
1995-12-22 |
2005-07-07 |
Amgen Inc. |
Combination therapy for conditions leading to bone loss
|
|
US7632922B1
(en)
*
|
1995-12-22 |
2009-12-15 |
Amgen, Inc. |
Osteoprotegerin
|
|
US6479254B2
(en)
|
1996-03-22 |
2002-11-12 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II
|
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
|
US6495520B2
(en)
|
1996-03-22 |
2002-12-17 |
Human Genome Sciences, Inc. |
Apoptosis Inducing Molecule II and methods of use
|
|
EP1803816A3
(en)
*
|
1996-12-13 |
2007-09-26 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
US6242213B1
(en)
|
1996-12-23 |
2001-06-05 |
Immunex Corporation |
Isolated DNA molecules encoding RANK-L
|
|
WO1999058674A2
(en)
|
1998-05-14 |
1999-11-18 |
Immunex Corporation |
Method of inhibiting osteoclast activity
|
|
PT946725E
(pt)
*
|
1996-12-23 |
2011-04-20 |
Immunex Corp |
Activador do receptor de nf-kappa b, o receptor é membro da superfamília do receptor tnf
|
|
AU2008200700C1
(en)
*
|
1997-04-15 |
2013-04-04 |
Daiichi Sankyo Co., Ltd |
Novel Protein and Process for Producing The Same
|
|
KR100496063B1
(ko)
|
1997-04-15 |
2005-06-21 |
산쿄 가부시키가이샤 |
신규단백질 및 그 제조방법
|
|
US6316408B1
(en)
*
|
1997-04-16 |
2001-11-13 |
Amgen Inc. |
Methods of use for osetoprotegerin binding protein receptors
|
|
EP0975754B2
(en)
*
|
1997-04-16 |
2016-01-06 |
Amgen Inc., |
Osteoprotegerin binding proteins and their receptors
|
|
CA2229449A1
(en)
*
|
1997-04-25 |
1998-10-25 |
Takeda Chemical Industries, Ltd. |
Novel receptor protein and its use
|
|
WO1998054201A1
(en)
*
|
1997-05-29 |
1998-12-03 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like protein 8
|
|
WO1999015691A1
(en)
|
1997-09-24 |
1999-04-01 |
Snow Brand Milk Products Co., Ltd. |
Method for diagnosing bone dysbolism
|
|
US7063960B2
(en)
|
1997-12-12 |
2006-06-20 |
The Rockefeller University |
Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
|
|
US7019119B2
(en)
|
1997-12-12 |
2006-03-28 |
The Rockefeller University |
Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
|
|
WO1999029865A2
(en)
*
|
1997-12-12 |
1999-06-17 |
The Rockefeller University |
A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
|
|
US20020106728A1
(en)
*
|
2000-06-20 |
2002-08-08 |
Genentech, Inc. |
NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
|
|
SI1114166T1
(en)
*
|
1998-09-15 |
2005-10-31 |
Pharmexa A/S |
Method for down-regulating osteoprotegerin ligand activity
|
|
CN1318105A
(zh)
*
|
1998-09-15 |
2001-10-17 |
M&E生物技术公司 |
负调节Osteoprotegerin配体活性的方法
|
|
US6534061B1
(en)
|
1999-04-12 |
2003-03-18 |
Genentech, Inc. |
Tumor necrosis factor receptor homologs and nucleic acids encoding the same
|
|
US6492124B1
(en)
|
1999-06-11 |
2002-12-10 |
The Rockefeller University |
Trance activated signal transduction pathways in osteoclasts
|
|
US6872806B1
(en)
*
|
1999-06-25 |
2005-03-29 |
The Governors Of The University Of Alberta |
Polypeptide compositions formed using a coiled-coil template and methods of use
|
|
CN101633692A
(zh)
|
1999-06-28 |
2010-01-27 |
杰南技术公司 |
利用二价金属离子制备Apo-2配体的方法
|
|
US6673771B1
(en)
|
1999-07-28 |
2004-01-06 |
The Trustees Of The University Of Pennsylvania |
Methods of inhibiting osteoclast activity
|
|
ATE448781T1
(de)
*
|
1999-07-28 |
2009-12-15 |
Univ Pennsylvania |
Methoden zur hemmung der aktivität der osteoklasten
|
|
AUPQ314799A0
(en)
*
|
1999-09-29 |
1999-10-21 |
University Of Western Australia, The |
Bone cell factor
|
|
US6171860B1
(en)
|
1999-11-05 |
2001-01-09 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of rank expression
|
|
AU1920301A
(en)
*
|
1999-11-17 |
2001-05-30 |
Immunex Corporation |
Receptor activator of nf-kappa b
|
|
GB9930616D0
(en)
|
1999-12-24 |
2000-02-16 |
Mathilda & Terence Kennedy Ins |
Activation and inhibition of the immune system
|
|
CA2396793A1
(en)
|
2000-02-16 |
2001-08-23 |
Genentech, Inc. |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
|
DK2105449T3
(da)
*
|
2000-02-23 |
2019-10-07 |
Amgen Inc |
Antagonistiske selektive bindemidler af osteoprotegerinbindende protein
|
|
US20030103978A1
(en)
*
|
2000-02-23 |
2003-06-05 |
Amgen Inc. |
Selective binding agents of osteoprotegerin binding protein
|
|
CN101289511A
(zh)
|
2000-04-11 |
2008-10-22 |
杰南技术公司 |
多价抗体及其应用
|
|
JP2003534022A
(ja)
*
|
2000-05-26 |
2003-11-18 |
スミスクライン・ビーチャム・コーポレイション |
Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
|
|
PT1303293E
(pt)
|
2000-07-27 |
2009-03-11 |
Genentech Inc |
Administração sequencial de cpt-11 e polipéptido apo-2l
|
|
WO2002016551A2
(en)
*
|
2000-08-18 |
2002-02-28 |
University Of Massachusetts Medical Center |
Trance regulation of chondrocyte differentiation
|
|
AU2001288342A1
(en)
*
|
2000-08-21 |
2002-03-04 |
Smith Kline Beecham Corporation |
Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
|
|
ATE366306T1
(de)
*
|
2000-09-22 |
2007-07-15 |
Immunex Corp |
Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b
|
|
US7128911B2
(en)
*
|
2001-01-19 |
2006-10-31 |
Cytos Biotechnology Ag |
Antigen arrays for treatment of bone disease
|
|
AU2002231602A1
(en)
*
|
2001-02-09 |
2002-08-28 |
Maxygen Holdings Ltd. |
Rank ligand-binding polypeptides
|
|
US20040132971A1
(en)
*
|
2001-02-09 |
2004-07-08 |
Haaning Jesper Mortensen |
Rank ligand-binding polypeptides
|
|
WO2002080955A1
(en)
*
|
2001-03-22 |
2002-10-17 |
Barnes-Jewish Hospital |
Stimulation of osteogenesis using rank ligand fusion proteins
|
|
US20030013651A1
(en)
*
|
2001-03-22 |
2003-01-16 |
Barnes-Jewish Hospital |
Stimulation of osteogenesis using rank ligand fusion proteins
|
|
US20050031583A1
(en)
*
|
2001-03-23 |
2005-02-10 |
Iqbal Grewal |
Uses of opg to modulate immune responses
|
|
US20040167072A1
(en)
*
|
2001-05-11 |
2004-08-26 |
Aggarwal Bharat B. |
Inhibitors of receptor activator of NF-kappaB and uses thereof
|
|
WO2002092623A1
(en)
*
|
2001-05-11 |
2002-11-21 |
Research Development Foundation |
INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF
|
|
US20030017151A1
(en)
*
|
2001-05-17 |
2003-01-23 |
Dougall William C. |
Therapeutic use of rank antagonists
|
|
US20040213788A1
(en)
*
|
2001-05-18 |
2004-10-28 |
Sweet Raymond W. |
Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
|
|
CA2449658A1
(en)
*
|
2001-06-06 |
2002-12-12 |
Immunex Corporation |
Use of rank antagonists to treat cancer
|
|
PH12012502440A1
(en)
|
2001-06-26 |
2013-06-17 |
Amgen Inc |
Antibodies to opgl
|
|
EP1414517A4
(en)
*
|
2001-06-26 |
2008-02-06 |
Photomed Technologies Inc |
Multiple wavelength illuminator
|
|
WO2003066661A2
(en)
|
2001-07-03 |
2003-08-14 |
Genentech, Inc. |
Human dr4 antibodies and uses thereof
|
|
US20030050223A1
(en)
*
|
2001-08-09 |
2003-03-13 |
Jonathan Lam |
Crystal forms and mutants of RANK ligand
|
|
IL161051A0
(en)
|
2001-10-02 |
2004-08-31 |
Genentech Inc |
Apo-2 ligand variants and uses thereof
|
|
CA2463478A1
(en)
*
|
2001-10-12 |
2003-08-14 |
Barnes-Jewish Hospital |
Methods for screening osteogenic compounds
|
|
US20030100068A1
(en)
*
|
2001-10-12 |
2003-05-29 |
Jonathan Lam |
RANKL mimics and uses thereof
|
|
US20030109444A1
(en)
*
|
2001-10-12 |
2003-06-12 |
Jonathan Lam |
Bone anti-resorptive compounds
|
|
IL161387A0
(en)
*
|
2001-10-15 |
2004-09-27 |
Barnes Jewish Hospital |
Rankl mimics and uses thereof
|
|
US7842668B1
(en)
|
2001-11-13 |
2010-11-30 |
Genentech, Inc. |
Apo-2 ligand/trail formulations
|
|
ES2351786T3
(es)
|
2001-11-13 |
2011-02-10 |
Genentech, Inc. |
Formulaciones con ligando apo2/trail y usos de las mismas.
|
|
US7741285B2
(en)
|
2001-11-13 |
2010-06-22 |
Genentech, Inc. |
APO-2 ligand/trail formulations
|
|
US7381792B2
(en)
*
|
2002-01-04 |
2008-06-03 |
Xencor, Inc. |
Variants of RANKL protein
|
|
AU2003217174A1
(en)
*
|
2002-01-04 |
2003-07-30 |
Xencor |
Novel variants of rankl protein
|
|
AU2003207464A1
(en)
*
|
2002-01-04 |
2003-07-24 |
Xencor |
Dominant negative proteins and methods thereof
|
|
US20040170602A1
(en)
*
|
2002-01-04 |
2004-09-02 |
Desjarlais John R. |
Dominant negative proteins and methods thereof
|
|
KR20030076448A
(ko)
*
|
2002-03-21 |
2003-09-26 |
주식회사 코메드 |
항-ｒａｎｋ 단클론 항체 및 이를 함유한 약학 조성물
|
|
WO2003086289A2
(en)
|
2002-04-05 |
2003-10-23 |
Amgen Inc. |
Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
|
|
CA2489348A1
(en)
|
2002-06-24 |
2003-12-31 |
Genentech, Inc. |
Apo-2 ligand/trail variants and uses thereof
|
|
US20040138162A1
(en)
*
|
2002-08-30 |
2004-07-15 |
Roodman G. David |
Method of resisting osteoclast formation
|
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
|
US7462700B2
(en)
*
|
2002-12-10 |
2008-12-09 |
Schering-Plough Animal Health Corporation |
Canine RANKL and methods for preparing and using the same
|
|
US7619060B2
(en)
*
|
2003-01-10 |
2009-11-17 |
Protein Crystal Co., Ltd. |
Cytoplasmic polyhedrosis virus protein complex of a polyhedrin and a VP3 polypeptide
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
WO2005028633A2
(en)
*
|
2003-09-17 |
2005-03-31 |
Isis Pharmaceuticals, Inc. |
Modulation of rankl expression
|
|
US7252833B2
(en)
*
|
2003-11-18 |
2007-08-07 |
Skeletal Kinetics, Llc |
Calcium phosphate cements comprising an osteoclastogenic agent
|
|
CA2551912A1
(en)
*
|
2003-12-29 |
2005-07-14 |
Toudai Tlo, Ltd. |
Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof
|
|
AU2005227322A1
(en)
|
2004-03-23 |
2005-10-06 |
Biogen Idec Ma Inc. |
Receptor coupling agents and therapeutic uses thereof
|
|
US8603824B2
(en)
|
2004-07-26 |
2013-12-10 |
Pfenex, Inc. |
Process for improved protein expression by strain engineering
|
|
MX2007001221A
(es)
|
2004-08-04 |
2007-03-23 |
Amgen Inc |
Anticuerpos para proteina dickkopf-1 (dkk-1).
|
|
PL1774037T3
(pl)
|
2004-08-06 |
2011-09-30 |
Genentech Inc |
Oznaczenia i sposoby wykorzystujące biomarkery
|
|
MX2007001469A
(es)
|
2004-08-06 |
2007-03-26 |
Genentech Inc |
Ensayos y metodos que utilizan biomarcadores.
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
EP2024396A2
(en)
*
|
2004-12-02 |
2009-02-18 |
Domantis Limited |
Plad domain peptides with increased serum half life due to conjugation to domain antibodies
|
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
|
JP5186372B2
(ja)
|
2005-08-16 |
2013-04-17 |
ジェネンテック， インコーポレイテッド |
細胞／組織においてｇａｌｎａｃ−ｔ１４発現を試験することによるａｐｏ２ｌ／ｔｒａｉｌに対するアポトーシス感受性
|
|
WO2007062090A2
(en)
|
2005-11-23 |
2007-05-31 |
Genentech, Inc. |
Methods and compositions related to b cell assays
|
|
US7795427B2
(en)
*
|
2006-02-14 |
2010-09-14 |
New York University |
Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
|
|
EP1854458A1
(en)
*
|
2006-05-08 |
2007-11-14 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Use of a compound with RANKL activity
|
|
EP2020445B1
(en)
|
2006-05-12 |
2013-01-02 |
Keio University |
Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease
|
|
KR101235439B1
(ko)
|
2006-10-11 |
2013-02-20 |
오리엔탈 이스트 컴파니 리미티드 |
가용형 ｒａｎｋｌ과 에피토프 태그의 융합 단백질을 포함하는 시약
|
|
WO2008044379A1
(fr)
|
2006-10-11 |
2008-04-17 |
Oriental Yeast Co., Ltd. |
Modèle animal de perte osseuse
|
|
WO2008044797A1
(fr)
|
2006-10-11 |
2008-04-17 |
Oriental Yeast Co., Ltd. |
Animal modèle d'ostéopénie
|
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
JP5444553B2
(ja)
|
2007-04-27 |
2014-03-19 |
フェネックス インコーポレイテッド |
微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法
|
|
JP5191487B2
(ja)
|
2007-06-05 |
2013-05-08 |
オリエンタル酵母工業株式会社 |
新しい骨量増加薬
|
|
CA2690568A1
(en)
*
|
2007-06-20 |
2008-12-24 |
Schering Corporation |
Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
|
|
ES2650224T3
(es)
|
2007-08-21 |
2018-01-17 |
Amgen, Inc. |
Proteínas de unión al antígeno C-FMS humano
|
|
KR100911852B1
(ko)
|
2007-11-26 |
2009-08-11 |
고려대학교 산학협력단 |
유세포 분석기를 이용한 신규한 ｒａｎｋ와 ｒａｎｋ리간드의 결합 분석방법
|
|
WO2009105934A1
(zh)
*
|
2008-02-27 |
2009-09-03 |
上海先导药业有限公司 |
抗人rankl单克隆抗体
|
|
TW201019959A
(en)
|
2008-08-19 |
2010-06-01 |
Regeneron Pharma |
Human antibodies to human RANKL
|
|
US8657662B2
(en)
|
2008-09-04 |
2014-02-25 |
Patent Investment & Licensing Company |
Gaming device having variable speed of play
|
|
WO2010038610A1
(ja)
|
2008-09-30 |
2010-04-08 |
オリエンタル酵母工業株式会社 |
新しい軟骨細胞増殖及び分化誘導剤
|
|
CN101712964B
(zh)
*
|
2008-10-08 |
2013-05-08 |
上海科新生物技术股份有限公司 |
抑制破骨细胞形成的融合蛋白、其制备方法及药物组合物
|
|
JP5773879B2
(ja)
|
2008-11-25 |
2015-09-02 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
神経系の細胞の生存を促進するためのＤＲ６およびｐ７５のアンタゴニストの使用
|
|
CN101514232B
(zh)
*
|
2009-03-25 |
2013-06-19 |
上海科新生物技术股份有限公司 |
一种RANKL-Fc融合蛋白及其制备方法和用途
|
|
EP2420515A4
(en)
*
|
2009-04-16 |
2013-08-28 |
Univ Tokyo |
DIAGNOSIS AND TREATMENT OF CANCER WITH ANTI-TMPRSS11E ANTIBODY
|
|
KR101153393B1
(ko)
*
|
2009-09-21 |
2012-06-07 |
고려대학교 산학협력단 |
점변이 이용한 수용성 재조합 인간 ｒａｎｋ의 효능 향상 및 골 질환 치료용 조성물
|
|
EP2552967A4
(en)
|
2010-04-02 |
2014-10-08 |
Amunix Operating Inc |
BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
|
|
SG10201505217WA
(en)
|
2010-07-09 |
2015-08-28 |
Biogen Hemophilia Inc |
Chimeric clotting factors
|
|
EP2434285A1
(en)
|
2010-09-22 |
2012-03-28 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Breast cancer diagnostics
|
|
EP2433644A1
(en)
|
2010-09-22 |
2012-03-28 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Breast cancer therapeutics
|
|
CN108192972B
(zh)
|
2010-10-06 |
2022-09-09 |
生物医学研究机构基金会 |
用于乳腺癌转移的诊断、预后和治疗的方法
|
|
JPWO2012133914A1
(ja)
|
2011-03-31 |
2014-07-28 |
オリエンタル酵母工業株式会社 |
Ｒａｎｋｌアンタゴニストを含む癌免疫増強剤
|
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
|
FR2980711A1
(fr)
*
|
2011-10-03 |
2013-04-05 |
Centre Nat Rech Scient |
Modulation du systeme immunitaire et des cellules stromales via rank
|
|
WO2013067639A1
(en)
|
2011-11-07 |
2013-05-16 |
UNIVERSITé LAVAL |
Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
|
|
EP2650682A1
(en)
|
2012-04-09 |
2013-10-16 |
Fundació Privada Institut de Recerca Biomèdica |
Method for the prognosis and treatment of cancer metastasis
|
|
BR112014030750A2
(pt)
|
2012-06-06 |
2017-08-22 |
Inst Catalana Recerca Estudis Avancats |
Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
|
|
ES2906586T3
(es)
|
2012-10-12 |
2022-04-19 |
Inbiomotion Sl |
Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata
|
|
US10119171B2
(en)
|
2012-10-12 |
2018-11-06 |
Inbiomotion S.L. |
Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
AR095527A1
(es)
|
2013-03-15 |
2015-10-21 |
Biogen Idec Inc |
Formulaciones de polipéptido fc-factor ix
|
|
WO2014184679A2
(en)
|
2013-03-15 |
2014-11-20 |
Inbiomotion S.L. |
Method for the prognosis and treatment of renal cell carcinoma metastasis
|
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
|
CA2906394A1
(en)
|
2013-03-15 |
2014-09-18 |
Fundacio Institut De Recerca Biomedica (Irb Barcelona) |
Method for the prognosis and treatment of cancer metastasis
|
|
CA2920376A1
(en)
|
2013-08-07 |
2015-02-12 |
Martin Blomberg JENSEN |
Methods and composition comprising denosumab or an antibody or antigen binding domain, fragment or derivative thereof, immunoreactive with a rankl/opgbp peptide for use in the treatment, prevention or alleviation of male infertility
|
|
WO2015030701A1
(en)
*
|
2013-08-24 |
2015-03-05 |
R-Pharm Overseas, Inc. |
Fully human antibodies against human rankl
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
EP3712166A1
(en)
|
2013-09-05 |
2020-09-23 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
|
DK3055429T3
(en)
|
2013-10-09 |
2019-04-23 |
Fundacio Inst De Recerca Biomedica Irb Barcelona |
Procedure for the prognosis and treatment of metastatic bone cancer resulting from breast cancer
|
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
|
FI3834824T3
(fi)
|
2014-03-28 |
2025-12-05 |
Univ Duke |
Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
|
|
US10156562B2
(en)
|
2014-05-16 |
2018-12-18 |
Amgen Inc. |
Assay for detecting Th1 and Th2 cell populations
|
|
KR20170093182A
(ko)
|
2014-12-11 |
2017-08-14 |
인바이오모션 에스.엘. |
인간 c-maf에 대한 결합 구성원
|
|
CN104829725A
(zh)
*
|
2015-01-21 |
2015-08-12 |
武汉友芝友生物制药有限公司 |
一种双特异性抗体cd133×cd3的构建及应用
|
|
JP7019422B2
(ja)
|
2015-04-29 |
2022-02-15 |
ラジウス ファーマシューティカルズ，インコーポレイテッド |
癌を治療するための方法
|
|
AU2016263030A1
(en)
*
|
2015-05-18 |
2017-10-12 |
Eli Lilly And Company |
Anti-Dkk-1-anti-RANKL bispecific antibody compounds
|
|
AU2016265523B2
(en)
*
|
2015-05-20 |
2019-07-18 |
Osaka University |
Oligopeptide having proinflammatory cytokine secretion-inhibiting activity
|
|
EP4349410A3
(en)
*
|
2016-01-05 |
2024-06-05 |
The Trustees Of Columbia University In The City Of New York |
A composition for use in the therapeutic treatment of a cancer or a tumor
|
|
WO2017123642A1
(en)
*
|
2016-01-12 |
2017-07-20 |
The Trustees Of The University Of Pennsylvania |
Methods and uses of osteoclast associated receptor (oscar) for prevention and treatment of osteoarthritis
|
|
CA3013443C
(en)
|
2016-02-01 |
2021-06-15 |
Eli Lilly And Company |
Parathyroid hormone - anti-rankl antibody fusion compounds
|
|
UA126115C2
(uk)
|
2016-03-08 |
2022-08-17 |
Янссен Байотек, Інк. |
Антитіло до gitr
|
|
US11596642B2
(en)
|
2016-05-25 |
2023-03-07 |
Inbiomotion S.L. |
Therapeutic treatment of breast cancer based on c-MAF status
|
|
US20190292254A1
(en)
|
2016-07-14 |
2019-09-26 |
Scholar Rock, Inc. |
TGFBeta Antibodies, Methods and Uses
|
|
KR20190052137A
(ko)
|
2016-10-28 |
2019-05-15 |
일라이 릴리 앤드 캄파니 |
항-rankl 항체 및 그의 용도
|
|
KR102707399B1
(ko)
|
2017-01-05 |
2024-09-13 |
래디어스 파마슈티컬스, 인코포레이티드 |
Rad1901-2hcl의 다형 형태
|
|
AU2018235928B2
(en)
|
2017-03-14 |
2023-09-21 |
Amgen Inc. |
Control of total afucosylated glycoforms of antibodies produced in cell culture
|
|
KR20200104298A
(ko)
|
2017-11-22 |
2020-09-03 |
인바이오모션 에스.엘. |
c-MAF 상태에 기반한 유방암의 요법 치료
|
|
BR112020019559A2
(pt)
|
2018-03-26 |
2021-01-12 |
Amgen Inc. |
Glicoformas afucosiladas totais de anticorpos produzidos em cultura de células
|
|
IL279853B2
(en)
|
2018-07-04 |
2025-01-01 |
Radius Pharmaceuticals Inc |
Polymorphic forms of RAD 1901-2HCL
|
|
US11499928B2
(en)
*
|
2018-08-24 |
2022-11-15 |
University Of Wyoming |
Methods and systems for isochoric measurements using differential scanning calorimetry
|
|
EP3860653A1
(en)
|
2018-10-05 |
2021-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and systems for controlling the agonistic properties of antibody variable domains by light
|
|
US11279698B2
(en)
|
2018-11-20 |
2022-03-22 |
Cornell University |
Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
|
|
CN113348163B
(zh)
|
2019-02-12 |
2024-10-08 |
雷迪厄斯制药公司 |
方法和化合物
|
|
MX2022003461A
(es)
|
2019-09-26 |
2022-04-19 |
Amgen Inc |
Metodos de produccion de composiciones de anticuerpos.
|
|
WO2021149012A1
(en)
|
2020-01-24 |
2021-07-29 |
Radius Health, Inc. |
Methods of stimulating bone growth with abalopartide and denosumab
|
|
CN111793135A
(zh)
*
|
2020-05-11 |
2020-10-20 |
廊坊天光生物技术有限公司 |
一种用于检测血清中rankl含量的抗体对及其用途
|
|
WO2021247892A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
|
AU2021360897A1
(en)
|
2020-10-15 |
2023-05-25 |
Amgen Inc. |
Relative unpaired glycans in antibody production methods
|
|
EP4352094A1
(en)
|
2021-06-07 |
2024-04-17 |
Amgen Inc. |
Using fucosidase to control afucosylation level of glycosylated proteins
|
|
AU2022361382A1
(en)
|
2021-10-05 |
2024-03-28 |
Amgen Inc. |
Fc-gamma receptor ii binding and glycan content
|
|
WO2023179791A1
(en)
*
|
2022-03-24 |
2023-09-28 |
Angitia Biomedicines Limited |
Treatment of musculoskeletal disorders
|
|
US20250249278A1
(en)
|
2022-04-14 |
2025-08-07 |
Institut National de la Santé et de la Recherche Médicale |
Methods for controlling the tumor cell killing by light
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2024220916A1
(en)
|
2023-04-20 |
2024-10-24 |
Amgen Inc. |
Methods of determining relative unpaired glycan content
|
|
WO2025038600A1
(en)
|
2023-08-14 |
2025-02-20 |
Amgen Inc. |
Methods for reducing yellow color
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|